X-ray Structure of Human ACMSD with TES-1025
TES Pharma announces the publication of a Frontiers in Molecular Biosciences, section Structural Biology paper “ Structural basis of human dimeric α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) inhibition with TES-1025” (doi.org/10.3389/fmolb.2022.834700) disclosing, by X-ray…
Prof. Roberto Pellicciari Recipient of the EFMC Honorary Fellow Award
TES Pharma is pleased to congratulate Prof Roberto Pellicciari as one of the first recipients of the EFMC Honorary Fellow Award. This prestigious award is part of the 50th anniversary…
POR FESR 2014-2020, Asse I, Azione 1.1.1. – Avviso Ricerca 2020 – Regione Umbria
“Ricerca e Sviluppo di Modulatori del NAD+ per il Trattamento della Disfunzione Epato-Renale in Pazienti COVID-19” Progetto finanziato dalla Regione Umbria nel quadro del “Avviso a sostegno dei progetti di ricerca e sviluppo…
POR FESR 2014-2020. Asse I Azione 1.1.1. – Regione Umbria
“Modulazione farmacologica dell’omeostasi della Nicotinamide Dinucleotide (NAD+) come approccio terapeutico innovativo per il trattamento dell’insulto renale acuto” Progetto finanziato dalla Regione Umbria nel quadro del “Avviso a sostegno dei progetti di ricerca…
Mitochondrial Dysfunction is a Key Driver of Acute Kidney Injury Pathophysiology
As highlighted in Nature Reviews Nephrology by Prof. John Kellum (Center for Critical Care Nephrology, Univ. of Pittsburgh) in his review of progress in the field of Acute Kidney Injury…
Targeting NAD+ Synthesis via inhibition of ACMSD to prevent NAFLD and AKI
Publishing in Nature, scientists lead Johan Auwerx at EPFL (Lausanne) and Roberto Pellicciari at TES Pharma have found a new way of increasing nicotinamide adenine dinucleotide (NAD+) in the kidney…
De novo NAD+ synthesis enhances mitochondrial function and improves health
TES Pharma announces the publication of a Nature paper “De novo NAD+ synthesis enhances mitochondrial function and improves health” (DOI: 10.1038/s41586-018-0645-6) reporting the in-vivo efficacy of our inhibitors of ACMSD in…
POR FESR 2014-2020 Regione Umbria
Progetto finanziato dalla Regione Umbria nel quadro del “Bando a sostegno dei progetti complessi di ricerca & sviluppo - POR FESR 2014-2020”. Il programma strategico “Piattaforma integrata per la ricerca e lo…
α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Inhibitors as Novel Modulators of NAD+ Biosynthesis
TES Pharma announces the publication of a Journal of Medicinal Chemistry paper “α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis” (DOI: 10.1021/acs.jmedchem.7b01254) covering the…
Umbria ERDF Project
TES announces the successful awarding of a European Regional Development Fund, Umbria project, "Integrated platform for innovative drug research and development for oncological and metabolic diseases ", partnered with leading…
First α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Patent Published
TES Pharma announces the granting of the first ACMSD patent, US9,708,272(B2), in its ACMSD patent portfolio. The patent discloses the first know drug-like inhibitors of ACMSD. Compounds from our ACMSD…
TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) Announce R&D Collaboration on Small Molecule Therapies for Metabolic Disorders and Age-Related Diseases
TES Pharma and EPFL announce a new research and development collaboration on novel small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases. The collaboration…